Request for Nominations for Nonvoting Members Representing Industry Interests on Public Advisory Committees, 14472-14473 [05-5551]
Download as PDF
<![CDATA[
14472
Federal Register / Vol. 70, No. 54 / Tuesday, March 22, 2005 / Notices
Medicare or Medicaid funds, and portions of
facilities used for inpatient drug or alcohol
treatment. Failure to comply with the
provisions of the law may result in the
imposition of a civil monetary penalty of up
to $1000 per day and/or the imposition of an
administrative compliance order on the
responsible entity. By signing and submitting
this application the applicant/grantee
certifies that it will comply with the
requirements of the Act.
The applicant/grantee further agrees that it
will require the language of this certification
be included in any subawards which contain
provisions for the children’s services and that
all subgrantees shall certify accordingly.
[FR Doc. 05–5555 Filed 3–21–05; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Request for Nominations for
Nonvoting Members Representing
Industry Interests on Public Advisory
Panels or Committees; Food Advisory
Committee
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is requesting
nominations for a nonvoting industry
representative to serve on the Food
Advisory Committee (the Committee) in
FDA’s Center for Food Safety and
Applied Nutrition (CFSAN).
DATES: Industry organizations interested
in participating in the selection of a
nonvoting member to represent industry
for the pending vacancy on the
Committee must send a letter to FDA by
April 21, 2005, stating their interest.
Concurrently, nomination materials for
prospective candidates should be sent to
FDA by April 21, 2005. A nominee may
either be self-nominated or nominated
by an organization to serve as a
nonvoting industry representative.
ADDRESSES: All letters of interest and
nominations should be sent to Marcia
Moore (see FOR FURTHER INFORMATION
CONTACT).
FOR FURTHER INFORMATION CONTACT:
Marcia Moore, Center for Food Safety
and Applied Nutrition (HFS–6), Food
and Drug Administration, 5100 Paint
Branch Pkwy., College Park, MD 20740,
301–436–2397, FAX 301–436–2633, email: marcia.moore@cfsan.fda.gov.
SUPPLEMENTARY INFORMATION: The
agency intends to fill a vacancy for a
nonvoting industry representative on
the Committee identified in section I of
this document.
VerDate jul<14>2003
15:26 Mar 21, 2005
Jkt 205001
I. Functions
The Advisory Committee Under the
Purview of CFSAN
Food Advisory Committee
The Committee shall provide advice
primarily to the Director of CFSAN, and
as needed to the Commissioner of Food
and Drugs (the Commissioner) and other
appropriate officials, on emerging food
safety, food science, nutrition, and other
food-related health issues that FDA
considers of primary importance for its
food and cosmetics programs. The
Committee may be charged with
reviewing and evaluating available data
and making recommendations on
matters such as those relating to the
following topics: (1) Broad scientific
and technical food or cosmetic related
issues, (2) the safety of new foods and
food ingredients, (3) labeling of foods
and cosmetics, (4) nutrient needs and
nutritional adequacy, and (5) safe
exposure limits for food contaminants.
The Committee also may be asked to
provide advice and make
recommendations on ways of
communicating to the public the
potential risks associated with these
issues and on approaches that might be
considered for addressing the issues.
II. Selection Procedure
Any organization in the food
manufacturing industry wishing to
participate in the selection of a
nonvoting member to represent industry
on the Committee should send a letter
stating that interest to the FDA contact
(see FOR FURTHER INFORMATION CONTACT)
within 30 days of publication of this
notice. Persons who nominate
themselves as an industry representative
for the Committee will not participate in
the selection process. It is, therefore,
recommended that nominations be
made by someone within an
organization, trade association, or firm
who is willing to participate in the
selection process. Within the
subsequent 30 days, FDA will send a
letter to each organization and a list of
all nominees along with their resumes.
The letter will state that the interested
organizations are responsible for
conferring with one another to select a
candidate, within 60 days after
receiving the letter, to serve as the
nonvoting member representing on the
Committee. If no individual is selected
within that 60 days, the Commissioner
may select the nonvoting member to
represent industry interests.
III. Application Procedure
Individuals may nominate themselves
or an organization representing the food
manufacturing industry may nominate
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
one or more individuals to serve as a
nonvoting industry representative. A
current curriculum vitae (which
includes the nominee’s business
address, telephone number, and e-mail
address) and the name of the committee
of interest should be sent to the FDA
contact person (see FOR FURTHER
INFORMATION CONTACT). FDA will
forward all nominations to the
organizations that have expressed
interest in participating in the selection
process for that committee.
FDA has a special interest in ensuring
that women, minority groups,
individuals with physical disabilities,
and small businesses are adequately
represented on its advisory committees.
Therefore, the agency encourages
nominations for appropriately qualified
candidates from these groups.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees.
Dated: March 14, 2005.
Shelia Dearybury Walcoff,
Associate Commissioner for External
Relations.
[FR Doc. 05–5552 Filed 3–21–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Request for Nominations for
Nonvoting Members Representing
Industry Interests on Public Advisory
Committees
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is requesting
nominations for nonvoting industry
representatives to serve on the National
Mammography Quality Assurance
Advisory Committee (NMQAAC) in the
Center for Devices and Radiological
Health (CDRH). FDA has a special
interest in ensuring that women,
minority groups, individuals with
disabilities, and small businesses are
adequately represented on its advisory
committees. Therefore, the agency
encourages nominations for
appropriately qualified candidates from
these groups.
DATES: Industry organizations interested
in participating in the selection of a
nonvoting member to represent industry
for the vacancies listed in this notice
must send a letter to FDA by April 21,
2005, stating their interest in the
E:\FR\FM\22MRN1.SGM
22MRN1
Federal Register / Vol. 70, No. 54 / Tuesday, March 22, 2005 / Notices
committee (NMQAAC). Concurrently,
nomination materials for prospective
candidates should be sent to FDA by
April 21, 2005. A nominee may either
be self-nominated or nominated by an
organization to serve as a nonvoting
industry representative.
ADDRESSES: All letters of interest and
nominations should be sent to the
contact person listed in the FOR FURTHER
INFORMATION section of this notice.
FOR FURTHER INFORMATION CONTACT:
Kathleen L. Walker, Center for Devices
and Radiological Health (HFZ–17), Food
and Drug Administration, 2098 Gaither
Rd., Rockville, MD 20850, 240–276–
0450, ext. 114.
SUPPLEMENTARY INFORMATION: The
Mammography Quality Standards
Reauthorization Act of 2004 (Public Law
108–365) requires the addition of at
least two industry representatives with
expertise in mammography equipment
to the National Mammography Quality
Assurance Advisory Committee.
I. Functions of NMQAAC
The functions of the NMQAAC are to
advise FDA on: (1) Developing
appropriate quality standards and
regulations for mammography facilities,
(2) developing appropriate standards
and regulations for bodies accrediting
mammography facilities under this
program, (3) developing regulations
with respect to sanctions, (4) developing
procedures for monitoring compliance
with standards, (5) establishing a
mechanism to investigate consumer
complaints, (6) reporting new
developments concerning breast
imaging which should be considered in
the oversight of mammography
facilities, (7) determining whether there
exists a shortage of mammography
facilities in rural and health
professional shortage areas and
determining the effects of personnel on
access to the services of such facilities
in such areas, (8) determining whether
there will exist a sufficient number of
medical physicists after October 1, 1999,
and (9) determining the costs and
benefits of compliance with these
requirements.
II. Selection Procedure
Any organization representing the
mammography device industry wishing
to participate in the selection of a
nonvoting member to represent industry
should send a letter stating that interest
to the FDA contact (see FOR FURTHER
INFORMATION CONTACT) within 30 days of
publication of this notice. Persons who
nominate themselves as industry
representatives will not participate in
the selection process. It is, therefore,
VerDate jul<14>2003
15:26 Mar 21, 2005
Jkt 205001
recommended that nominations be
made by someone within an
organization, trade association or firm
who is willing to participate in the
selection process. Within the
subsequent 30 days, FDA will send a
letter to each organization and a list of
all nominees along with their resumes.
The letter will state that the interested
organizations are responsible for
conferring with one another to select a
candidate, within 60 days after
receiving the letter, to serve as the
nonvoting member representing the a
particular committee. If no individual is
selected within the 60 days, the
Commissioner of Food and Drugs (the
Commissioner) may select the
nonvoting member to represent industry
interests.
III. Qualifications
Persons nominated for membership
on the committee as an industry
representative must meet the following
criteria:(1) Demonstrate expertise in
mammography equipment and (2) be
able to discuss equipment specifications
and quality control procedures affecting
mammography equipment. The industry
representative must be able to represent
the industry perspective on issues and
actions before the advisory committee;
serve as liaison between the committee
and interested industry parties; and
facilitate dialogue with the advisory
committee on mammography equipment
issues.
IV. Application Procedure
Individuals may nominate
themselves, or an organization
representing the mammography device
industry may nominate one or more
individuals to serve as nonvoting
industry representatives. A current
curriculum vitae (which includes the
nominee’s business address, telephone
number, and e-mail address) and the
name of the committee of interest
should be sent to the FDA contact
person. FDA will forward all
nominations to the organizations that
have expressed interest in participating
in the selection process for the
committee.
FDA has a special interest in ensuring
that women, minority groups,
individuals with disabilities, and small
businesses are adequately represented
on its advisory committees. Therefore,
the agency encourages nominations for
appropriately qualified candidates from
these groups.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14
relating to advisory committees.
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
14473
Dated: March 14, 2005.
Sheila Dearybury Walcoff,
Associate Commissioner for External
Relations.
[FR Doc. 05–5551 Filed 3–21–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Toxicology Program; National
Toxicology Program (NTP) Interagency
Center for the Evaluation of Alternative
Toxicological Methods (NICEATM);
Request for Nominations for an
Independent Peer Review Panel To
Evaluate In Vitro Testing Methods for
Estimating Acute Oral Systemic
Toxicity and Request for In Vivo and In
Vitro Data
National Institute of
Environmental Health Sciences
(NIEHS), National Institutes of Health
(NIH), HHS.
ACTION: Request for nominations for an
independent peer review panel and
request for in vivo and in vitro data.
AGENCY:
SUMMARY: The NTP Interagency Center
for Evaluation of Alternative
Toxicological Methods (NICEATM) in
collaboration with the Interagency
Coordinating Committee on the
Validation of Alternative Methods
(ICCVAM) is planning to convene an
independent peer review panel
(hereafter, Panel) to evaluate the
validation status of two in vitro
cytotoxicity assays for estimating in vivo
acute oral toxicity. The Panel will
evaluate the usefulness, limitations,
accuracy, and reliability of these test
methods for their intended purpose.
NICEATM requests nominations of
expert scientists for consideration as
potential Panel members. ICCVAM will
consider the conclusions and
recommendations from the Panel in
developing test method
recommendations and performance
standards for these test methods. Data
from standard in vivo acute oral toxicity
testing and in vitro cytotoxicity testing
also is requested.
DATES: Nominations and data should be
received by noon on May 6, 2005.
ADDRESSES: Nominations and data
should be sent by mail, fax, or e-mail to
Dr. William S. Stokes, Director of
NICEATM, at NICEATM, NIEHS, P.O.
Box 12233, MD EC–17, Research
Triangle Park, NC 27709, (phone) 919–
541–2384, (fax) 919–541–0947, (e-mail)
niceatm@niehs.nih.gov. Courier address:
NICEATM, 79 T.W. Alexander Drive,
E:\FR\FM\22MRN1.SGM
22MRN1
]]>Agencies
[Federal Register Volume 70, Number 54 (Tuesday, March 22, 2005)]
[Notices]
[Pages 14472-14473]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-5551]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Request for Nominations for Nonvoting Members Representing
Industry Interests on Public Advisory Committees
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is requesting
nominations for nonvoting industry representatives to serve on the
National Mammography Quality Assurance Advisory Committee (NMQAAC) in
the Center for Devices and Radiological Health (CDRH). FDA has a
special interest in ensuring that women, minority groups, individuals
with disabilities, and small businesses are adequately represented on
its advisory committees. Therefore, the agency encourages nominations
for appropriately qualified candidates from these groups.
DATES: Industry organizations interested in participating in the
selection of a nonvoting member to represent industry for the vacancies
listed in this notice must send a letter to FDA by April 21, 2005,
stating their interest in the
[[Page 14473]]
committee (NMQAAC). Concurrently, nomination materials for prospective
candidates should be sent to FDA by April 21, 2005. A nominee may
either be self-nominated or nominated by an organization to serve as a
nonvoting industry representative.
ADDRESSES: All letters of interest and nominations should be sent to
the contact person listed in the FOR FURTHER INFORMATION section of
this notice.
FOR FURTHER INFORMATION CONTACT: Kathleen L. Walker, Center for Devices
and Radiological Health (HFZ-17), Food and Drug Administration, 2098
Gaither Rd., Rockville, MD 20850, 240-276-0450, ext. 114.
SUPPLEMENTARY INFORMATION: The Mammography Quality Standards
Reauthorization Act of 2004 (Public Law 108-365) requires the addition
of at least two industry representatives with expertise in mammography
equipment to the National Mammography Quality Assurance Advisory
Committee.
I. Functions of NMQAAC
The functions of the NMQAAC are to advise FDA on: (1) Developing
appropriate quality standards and regulations for mammography
facilities, (2) developing appropriate standards and regulations for
bodies accrediting mammography facilities under this program, (3)
developing regulations with respect to sanctions, (4) developing
procedures for monitoring compliance with standards, (5) establishing a
mechanism to investigate consumer complaints, (6) reporting new
developments concerning breast imaging which should be considered in
the oversight of mammography facilities, (7) determining whether there
exists a shortage of mammography facilities in rural and health
professional shortage areas and determining the effects of personnel on
access to the services of such facilities in such areas, (8)
determining whether there will exist a sufficient number of medical
physicists after October 1, 1999, and (9) determining the costs and
benefits of compliance with these requirements.
II. Selection Procedure
Any organization representing the mammography device industry
wishing to participate in the selection of a nonvoting member to
represent industry should send a letter stating that interest to the
FDA contact (see FOR FURTHER INFORMATION CONTACT) within 30 days of
publication of this notice. Persons who nominate themselves as industry
representatives will not participate in the selection process. It is,
therefore, recommended that nominations be made by someone within an
organization, trade association or firm who is willing to participate
in the selection process. Within the subsequent 30 days, FDA will send
a letter to each organization and a list of all nominees along with
their resumes. The letter will state that the interested organizations
are responsible for conferring with one another to select a candidate,
within 60 days after receiving the letter, to serve as the nonvoting
member representing the a particular committee. If no individual is
selected within the 60 days, the Commissioner of Food and Drugs (the
Commissioner) may select the nonvoting member to represent industry
interests.
III. Qualifications
Persons nominated for membership on the committee as an industry
representative must meet the following criteria:(1) Demonstrate
expertise in mammography equipment and (2) be able to discuss equipment
specifications and quality control procedures affecting mammography
equipment. The industry representative must be able to represent the
industry perspective on issues and actions before the advisory
committee; serve as liaison between the committee and interested
industry parties; and facilitate dialogue with the advisory committee
on mammography equipment issues.
IV. Application Procedure
Individuals may nominate themselves, or an organization
representing the mammography device industry may nominate one or more
individuals to serve as nonvoting industry representatives. A current
curriculum vitae (which includes the nominee's business address,
telephone number, and e-mail address) and the name of the committee of
interest should be sent to the FDA contact person. FDA will forward all
nominations to the organizations that have expressed interest in
participating in the selection process for the committee.
FDA has a special interest in ensuring that women, minority groups,
individuals with disabilities, and small businesses are adequately
represented on its advisory committees. Therefore, the agency
encourages nominations for appropriately qualified candidates from
these groups.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14 relating to advisory committees.
Dated: March 14, 2005.
Sheila Dearybury Walcoff,
Associate Commissioner for External Relations.
[FR Doc. 05-5551 Filed 3-21-05; 8:45 am]
BILLING CODE 4160-01-S
